FDA calendar · January 2022 · built from SEC filings

PDUFA dates January 2022: FDA calendar and catalysts.

Updated Snapshot 20261116T112050ZBuilt

0 PDUFA dates fell in January 2022. The FDA calendar also recorded 27 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in January 2022

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

January 2022: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Jan 2022Month disclosedcorticotropinANIPLabel expansion—ApprovedSEC 8-K Exhibit 99.1
January 7, 2022Genvoya (cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
January 7, 2022Descovy (emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
January 13, 2022Topamax Sprinkle (topiramate)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
January 14, 2022RINVOQ® (upadacitinib)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
January 14, 2022Cibinqo (abrocitinib)PFEFDA approvalTo treat refractory, moderate-to-severe atopic dermatitisApprovedFDA Novel Drug Approvals
January 20, 2022Dovato (dolutegravir sodium; lamivudine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
January 21, 2022Skyrizi (risankizumab-rzaa)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
January 21, 2022Veklury (remdesivir)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
January 21, 2022Ngenla (somatrogon-ghla)PFEComplete Response Letter—CRL issuedFDA Complete Response Letters
January 24, 2022Rukobia (fostemsavir tromethamine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
January 25, 2022Daptomycin (daptomycin)BAXFDA approval—ApprovedopenFDA Drugs@FDA
January 25, 2022Kimmtrak (tebentafusp-tebn)IMCRFDA approvalTo treat unresectable or metastatic uveal melanomaApprovedFDA Novel Drug Approvals
January 26, 2022Solosec (secnidazole)EVFMLabel expansion—ApprovedopenFDA Drugs@FDA
January 27, 2022Pifeltro (doravirine)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
January 27, 2022Delstrigo (doravirine; lamivudine; tenofovir disoproxil fumarate)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
January 28, 2022Tafinlar (dabrafenib mesylate)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
January 28, 2022Mekinist (trametinib dimethyl sulfoxide)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
January 28, 2022Geodon (ziprasidone hydrochloride)VTRSLabel expansion—ApprovedopenFDA Drugs@FDA
January 31, 2022LYNPARZA® (olaparib)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
January 31, 2022Vocabria (cabotegravir sodium)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
January 31, 2022Cabenuva Kit (cabotegravir; rilpivirine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
January 31, 2022Edurant Ped (rilpivirine hydrochloride)JNJLabel expansion—ApprovedopenFDA Drugs@FDA

January 2022: dated readouts

DateDrugCompanyEventIndicationStatusSource
Jan 2022Month disclosedISEMBYLD (apitegromab)SRRKTopline readoutwith Type 2 and Type 3 SMA and in October 2024, wePositiveSEC Form 10-Q

January 2022: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Jan 2022Month disclosedISEMBYLD (apitegromab)SRRKTrial startwith Type 2 and Type 3 SMA and in October 2024, weCompletedSEC Form 10-Q
Jan 2022Month disclosedHMPL-653HCMTrial startadvanced or metastatic solid tumors and TGCTCompletedSEC Form 10-K
Jan 2022Month disclosedTLX591TLXTrial start—CompletedSEC Form 10-K

Questions

What PDUFA dates are in January 2022?

0 PDUFA dates fell in January 2022. The FDA calendar also recorded 27 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.